Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Expert Rev Vaccines. 2015 Mar 31;14(6):815–831. doi: 10.1586/14760584.2015.1027690

Figure 6.

Figure 6

(a) Chemical structure of the primary gp120 V1V2 glycopeptide target bearing two closely spaced Man5GlcNAc2 N-linked glycans (Asn160 and Asn156) as epitope mimic of PG9 BnAb. (b) Stucture of simplified N-linked glycans (Man3GlcNAc2 and GlcNAc2) also incorporated into the V1V2 peptide backbone to gain access to additional simpler glycoforms. (c) Chemical synthesis of Man5GlcNAc2-bearing V1V2 glycopeptide via Native Chemical Ligation (pseudoproline dipeptide used to prevent aspartamide formation shown in red).